Earnout Provisions M&A: Bridging the Valuation Gap

Key Takeaways

• An earnout defers part of the purchase price contingent on the target hitting revenue, EBITDA, or milestone targets over 1–3 years post-close.
• EBITDA and revenue metrics are the most common but also the most manipulable by the buyer through expense allocation and pricing decisions.
• Sellers who rely on the implied covenant of good faith without express operating covenants routinely lose Delaware earnout disputes.
• Industry surveys show that a substantial portion of earnouts pay out less than the seller modeled at signing; treat full earnout as upside, not baseline.

What It Is

An earnout is contingent consideration. Part of the purchase price is fixed at closing and paid in cash or stock. Another part is deferred and linked to the target's performance over a measurement period that typically runs one to three years, sometimes longer. Common metrics include revenue, EBITDA, gross margin, product launches, FDA approvals, or other milestones that reflect the business's operating trajectory.

If the target hits the milestones, the seller receives the full earnout. If it falls short, the seller receives a reduced payout or nothing. Earnouts are used heavily in private-target deals involving growth companies, regulated assets such as drug candidates, and founder-led businesses whose future performance depends on the seller's continuing engagement.

The Intuition

Buyers and sellers of private companies often disagree on value. The seller believes in a trajectory the buyer cannot verify from two years of audited financials. The buyer does not want to overpay if growth slows. An all-cash, all-at-closing deal forces one side to absorb the disagreement.

An earnout splits the risk. The buyer pays a conservative amount up front and agrees to pay more if performance validates the seller's thesis. The seller gets a floor at closing and upside if the forecast proves out. When both sides believe in the business but differ on pace, an earnout can close a negotiation that would otherwise die.

The catch is that earnouts are famously prone to dispute. Once the seller hands over the business, the buyer controls the operations that determine whether milestones are hit. Delaware courts have developed a significant body of case law on whether the buyer met its good-faith obligations during the earnout period.

How It Works

Metric selection. The metric has to be both measurable and controllable by the business. Revenue is simple to audit but can be influenced by pricing and discounting decisions made by the buyer. EBITDA introduces expense lines that the buyer can push up or down. Product milestones (approvals, launches) are binary and cleaner, but concentrate risk in a single event.

Measurement period. One to three years is standard for operating metrics. Longer periods appear in biotech deals linked to approvals and sales ramps, sometimes stretching five to ten years for contingent value rights (CVRs).

Payment structure. Earnouts can be all-or-nothing (hit the target, get paid; miss, get nothing), linear (payment scales with achievement), tiered (defined steps), or cumulative (unused capacity rolls into later periods). Caps and floors are common to bound both sides' exposure.

Operating covenants. Well-drafted earnouts include covenants governing how the buyer must run the target during the earnout period. These may include obligations to maintain the business in substantially the same manner as before closing, to provide adequate resources, or to avoid specific actions that would impair the ability to hit the milestones. The strength of these covenants is often the single biggest driver of earnout litigation outcomes.

Implied covenant of good faith. Even when the contract is silent, Delaware courts hold buyers to an implied covenant of good faith and fair dealing with respect to earnout performance. A buyer who deliberately tanks sales to avoid paying the earnout can face damages. However, the courts have also consistently held that the implied covenant does not require the buyer to run the business in a way that maximizes the earnout at the expense of other legitimate business objectives. The line between the two is fact-intensive and heavily litigated.

Acceleration and change-of-control protection. Sellers often negotiate for acceleration if the buyer resells the business, shuts down the acquired product line, or suffers a change of control during the earnout period. Without these provisions, the seller can be stranded if the buyer's priorities shift.

Worked Example

Seller sells a $100 million revenue specialty-chemicals business. The valuation negotiation produces:

• $200 million cash at closing.
• Earnout of up to $100 million over three years, tied to cumulative EBITDA.
• Threshold: cumulative EBITDA of $60 million over three years earns $50 million of the earnout.
• Full payout of $100 million if cumulative EBITDA reaches $90 million.
• Linear scaling between the thresholds.

Year 1 EBITDA: $18 million. Year 2: $22 million. Year 3: $25 million. Cumulative: $65 million.

Earnout earned: 50 million plus (65 minus 60) divided by (90 minus 60) times 50 million equals 50 plus 8.33 equals roughly $58.3 million.

Total consideration: $258.3 million. The seller hit partial earnout. If the buyer had cut marketing spend by half during year 2, the seller could sue under operating covenants or the implied covenant of good faith, arguing the reduction impaired the ability to hit the $90 million target.

Common Mistakes

1. Picking metrics the buyer can manipulate. EBITDA is flexible by design. Revenue can be managed through discounting or channel loading. Product-approval milestones are harder to game but concentrate risk. Metric choice is the single most consequential part of the deal.

2. Skipping operating covenants. A purchase agreement that sets a metric but does not constrain how the buyer runs the business is a weak earnout. Delaware courts will apply the implied covenant, but express covenants give sellers far more leverage.

3. Assuming the implied covenant is broad protection. Delaware case law frequently rejects implied-covenant claims where express covenants exist and speak to the issue. Sellers who rely on implied protections rather than negotiating express ones often lose.

4. Ignoring acquirer consolidation and accounting changes. A target folded into a buyer's larger business can produce EBITDA that no one can cleanly measure because of shared services, transfer pricing, and allocation. Earnouts need separate accounting rules.

5. Overestimating collection odds. Industry studies (ABA and SRS Acquiom deal-point surveys) consistently show that a substantial portion of earnouts pay less than initially modeled. Sellers who treat the earnout as a near-certainty at signing tend to be disappointed at payout.

Frequently Asked Questions

Q: What is an earnout in simple terms? An earnout is a portion of the deal price that is paid only after closing, if the acquired business hits agreed performance targets over one to three years. It bridges a valuation gap: the buyer pays a floor now and the seller earns more if the growth story proves out.

Q: How do earnout provisions affect investment decisions? In public-company deals, earnouts are rare and signal genuine valuation disagreement. When present, investors should model the full earnout as upside rather than base case. Industry data consistently shows most earnouts pay out less than the seller expected at signing.

Q: What is a real-world example of an earnout dispute? A specialty-chemicals seller accepts $200M at closing plus up to $100M in an EBITDA-linked earnout. After the buyer cuts marketing spend in year 2, cumulative EBITDA falls short of the full threshold. The seller sues under the operating covenants, claiming the spending cut impaired performance. The case turns on whether the covenants were express or implied.

Q: How can sellers protect themselves in earnout negotiations? Negotiate express operating covenants, written obligations on how the buyer must run the business during the earnout period. Avoid metrics the buyer can manipulate (EBITDA via expense loading, revenue via discounting). Add change-of-control acceleration if the buyer resells or shuts down the acquired business.

Q: How is an earnout different from a contingent value right (CVR)? Both are contingent payments tied to post-closing milestones, but CVRs are typically issued in public-company deals, are securities (sometimes tradeable), and are often linked to single binary events like FDA approvals. Earnouts are private contractual arrangements in private-target deals, usually linked to operating metrics over a multi-year window.

Sources

1. Harvard Law School Forum on Corporate Governance. "Earnouts in M&A." https://corpgov.law.harvard.edu/2019/06/12/earnouts-in-m-a/
2. Harvard Law School Forum on Corporate Governance. "Earnouts in Delaware M&A Litigation." https://corpgov.law.harvard.edu/2021/05/05/earnouts-in-delaware-ma-litigation/
3. SRS Acquiom. "M&A Deal Terms Study." https://www.srsacquiom.com/resources/ma-deal-terms-study/
4. American Bar Association. "Private Target Mergers & Acquisitions Deal Points Study." https://www.americanbar.org/groups/business_law/committees/ma/

Disclaimer

This article is educational content only and is not financial advice. Nothing here is a recommendation to buy, sell, or hold any security. Consult a licensed advisor before making investment decisions.